Want to see HK:3692 full AI Analyst Report?
Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$41.00
▲(29.17% Upside)
Action:Reiterated
Date:08/28/26
The score is driven primarily by strong financial performance (high profitability, low leverage, and solid cash generation). This is tempered by mixed-to-weak near-term technical momentum (negative MACD and low stochastic despite being above key moving averages) and a less attractive valuation profile (P/E ~28.9 with a modest 1.17% yield).
Positive Factors
Revenue Growth and Profitability
The return to double-digit growth alongside exceptionally high margins indicates strong product economics and commercial execution. Sustained profitability can support reinvestment in R&D, launches and market access across oncology, CNS and chronic-care franchises.
Negative Factors
Operating Margin Volatility
Margin changes across years suggest profitability is not entirely stable and may be affected by product mix, launch costs or competitive pricing. Persistent volatility could make earnings less predictable and constrain confidence in long-term margin durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Profitability
The return to double-digit growth alongside exceptionally high margins indicates strong product economics and commercial execution. Sustained profitability can support reinvestment in R&D, launches and market access across oncology, CNS and chronic-care franchises.
Read all positive factors
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$218.79B
Dividend Yield1.24%
Average Volume (3M)12.29M
Price to Earnings (P/E)27.1
Beta (1Y)0.49
Revenue Growth24.97%
EPS Growth43.23%
CountryHK
Employees9,643
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.10
Shares Outstanding6,064,150,000
10 Day Avg. Volume13,877,970
30 Day Avg. Volume12,287,815
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.60Price Target Upside46.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)1.06
Revenue Forecast (FY)HK$16.98B
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Company Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic area...
How the Company Makes Money
Hansoh primarily makes money by selling pharmaceutical products (mainly prescription medicines) in mainland China. Revenue is generated from (1) in-house manufactured finished drugs sold to customers via the company’s commercialization network and...
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.90B | 15.03B | 12.26B | 10.10B | 9.38B | 9.94B |
| Gross Profit | 14.38B | 13.51B | 11.16B | 9.07B | 8.51B | 9.06B |
| EBITDA | 6.30B | 5.77B | 4.28B | 4.20B | 2.93B | 3.08B |
| Net Income | 6.68B | 5.56B | 4.37B | 3.28B | 2.58B | 2.71B |
Balance Sheet | ||||||
| Total Assets | 46.60B | 39.92B | 31.66B | 33.04B | 30.00B | 27.16B |
| Cash, Cash Equivalents and Short-Term Investments | 37.38B | 31.58B | 23.39B | 24.86B | 21.63B | 18.94B |
| Total Debt | 4.23B | 105.14M | 117.89M | 4.30B | 4.38B | 3.83B |
| Total Liabilities | 8.84B | 4.54B | 2.98B | 7.24B | 7.35B | 7.13B |
| Stockholders Equity | 37.76B | 35.38B | 28.68B | 25.79B | 22.65B | 20.03B |
Cash Flow | ||||||
| Free Cash Flow | 3.77B | 6.25B | 3.64B | 2.90B | 2.47B | 2.12B |
| Operating Cash Flow | 3.95B | 6.74B | 3.86B | 3.12B | 2.74B | 2.58B |
| Investing Cash Flow | -6.39B | -7.15B | -1.39B | 1.07B | -5.94B | -2.26B |
| Financing Cash Flow | 1.51B | 1.55B | -6.07B | -753.70M | -818.14M | 3.42B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Positive
31.74
Price Trends
33.14
Positive
33.31
Positive
35.37
Positive
Market Momentum
0.94
Negative
59.79
Neutral
80.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Positive. The current price of 31.74 is below the 20-day moving average (MA) of 34.18, below the 50-day MA of 33.14, and below the 200-day MA of 35.37, indicating a bullish trend. The MACD of 0.94 indicates Negative momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 80.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3692.
Hansoh Pharmaceutical Group Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$218.79B | 27.06 | 18.26% | 1.24% | 24.97% | 43.23% | |
69 Neutral | HK$25.01B | 14.47 | 11.97% | 7.74% | -5.90% | -18.84% | |
68 Neutral | HK$28.21B | 5.95 | 7.92% | 5.36% | 7.94% | 52.83% | |
61 Neutral | HK$26.93B | 15.42 | 8.60% | 3.08% | 14.80% | -2.88% | |
60 Neutral | HK$19.28B | 150.13 | 1.43% | ― | -8.55% | -96.20% | |
59 Neutral | HK$65.80B | 17.53 | 6.97% | 2.60% | 9.88% | 9.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3692
Hansoh Pharmaceutical Group Company Limited
34.80
-3.28
-8.62%
HK:0013
HUTCHMED (China)
21.78
-3.30
-13.16%
HK:0867
China Medical System Holdings
11.18
-2.77
-19.86%
HK:1513
Livzon Pharmaceutical Group
21.24
-13.29
-38.49%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.29
-9.07
-34.41%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.47
-0.26
-5.52%
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh boosts profit on innovative drugs as lung cancer portfolio wins EU and China approvals
Aug 26, 2026
Hansoh Pharmaceutical Group reported strong interim results for the six months ended June 30, 2026, with revenue rising 11.7% to RMB8.304 billion and innovative medicines contributing RMB7.092 billion, or 85.4% of total sales. Profit surged 35.8% ...
Hansoh Pharmaceutical Declares Interim Dividend for First Half of 2026
Aug 26, 2026
Hansoh Pharmaceutical Group Company Limited has declared an interim ordinary cash dividend of HKD 0.285 per share for the six months ended June 30, 2026, for the financial year ending December 31, 2026. The ex-dividend date is set for September 22...
Hansoh Pharma Wins NMPA Nod for Clinical Trials of New Cholesterol Drug
Aug 6, 2026
Hansoh Pharmaceutical Group said its self-developed Class 1 innovative drug candidate HS-10582, formulated as tablets, has received clinical trial approval from China’s National Medical Products Administration. The company plans to evaluate ...
Hansoh Pharmaceutical Schedules Board Meeting to Approve Interim Results and Dividend
Aug 4, 2026
Hansoh Pharmaceutical Group Company Limited plans to convene a board meeting on August 26, 2026, to review and approve its interim financial results for the six months ended June 30, 2026. The board will also consider the declaration of an interim...
Hansoh’s Osteosarcoma Drug HS-20093 Hits Phase III Target, China Filing Planned
Jul 28, 2026
Hansoh Pharmaceutical said its proprietary B7-H3 directed antibody-drug conjugate HS-20093 achieved the primary endpoint in a pivotal Phase III trial for osteosarcoma patients who had progressed or relapsed after at least two prior systemic therap...
Hansoh Pharma Licenses IL-23 Drug to Avere and Gains Major Stake in Nasdaq-Bound Merger
Jul 14, 2026
Hansoh Pharmaceutical Group has granted Avere Therapeutics an exclusive license to develop, manufacture and commercialize its oral IL-23 receptor antagonist HS-20118 (AVR-001) globally outside Greater China. The deal entitles Hansoh to US$120 mill...
Hansoh Pharma’s HS-20093 Meets Phase III Survival Goal in Small Cell Lung Cancer
Jul 10, 2026
Hansoh Pharmaceutical Group has reported that its self-developed B7-H3 directed antibody-drug conjugate HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for advanced or relapsed small cell lung cancer patient...
Hansoh Pharma Wins NMPA Trial Approvals for New Metabolic Injection
Jul 2, 2026
Hansoh Pharmaceutical Group Company Limited, a Hong Kong-listed innovator in prescription medicines, is expanding its pipeline of Class 1 innovative drugs targeting chronic and high-prevalence conditions in China. The group relies on strong intern...
Hansoh Pharmaceutical Shareholders Approve All Resolutions at 2026 AGM
Jun 26, 2026
Hansoh Pharmaceutical Group reported that all resolutions at its June 26, 2026 annual general meeting were approved by shareholders via poll, including adoption of the 2025 audited financial statements and the declaration of a final dividend, sign...
Hansoh Pharma Wins NMPA Nod to Review New Injection for Kidney-Disease Complication
Jun 10, 2026
Hansoh Pharmaceutical said China’s National Medical Products Administration has accepted its New Drug Application for HS-10568 Injection, an innovative therapy for secondary hyperparathyroidism in adult chronic kidney disease patients underg...
Hansoh Pharmaceutical Reshapes Governance Team With New Joint Company Secretary
Jun 10, 2026
Hansoh Pharmaceutical has announced a change in its corporate governance team, with joint company secretary Zhong Shengli resigning effective June 10, 2026, after confirming she has no disagreements with the board or issues requiring shareholder a...
Hansoh Pharma Sets 2026 AGM to Approve 2025 Results, Dividend and Share Mandates
Jun 4, 2026
Hansoh Pharmaceutical Group has called its annual general meeting for June 26, 2026 in Hong Kong, where shareholders will review and adopt the 2025 audited financial statements and consider a proposed final dividend. The agenda also includes re-el...
Hansoh Pharma’s Weight-Loss Drug Olatorepatide Wins NDA Acceptance in China
Jun 3, 2026
Hansoh Pharmaceutical said China’s National Medical Products Administration has accepted its New Drug Application for Olatorepatide Injection, a self-developed, once-weekly GLP-1/GIP receptor dual agonist for chronic weight management in obe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.